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Abstract 23 
The hemagglutinin (HA), a glycoprotein on the surface of influenza A virus (IAV), 24 
initiates the virus life cycle by binding to terminal sialic acid (SA) residues on host cells. The HA 25 
gradually accumulates amino acid (aa) substitutions that allow IAV to escape immunity through 26 
a mechanism known as antigenic drift. We recently confirmed that a small set of aa residues are 27 
largely responsible for driving antigenic drift in swine-origin H3 IAV. All identified residues are 28 
located adjacent to the HA receptor binding site (RBS), suggesting that substitutions associated 29 
with antigenic drift may also influence receptor binding. Among those substitutions, residue 145 30 
was shown to be a major determinant of antigenic evolution. To determine whether there are 31 
functional constraints to substitutions near the RBS and their impact on receptor binding and 32 
antigenic properties, we carried out site-directed mutagenesis experiments at the single aa level. 33 
We generated a panel of viruses carrying substitutions at residue 145 representing all 20 amino 34 
acids. Despite limited amino acid usage in nature, most substitutions at residue 145 were well 35 
tolerated without major impact on virus replication in vitro. All substitutions retained receptor 36 
binding specificity, but frequently led to decreased receptor binding. Glycan microarray analysis 37 
showed that substitutions at residue 145 modulate binding to a broad range of glycans. 38 
Furthermore, antigenic characterization identified specific substitutions at residue 145 that 39 
altered antibody recognition. This work provides a better understanding of the functional effects 40 
of aa substitutions near the RBS and the interplay between receptor binding and antigenic drift. 41 
Importance 42 
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The complex and continuous antigenic evolution of IAVs remains a major hurdle for vaccine 43 
selection and effective vaccination. On the virus’ hemagglutinin (HA) of the H3N2 IAVs, the aa 44 
substitution N145K causes significant antigenic changes. We show that aa 145 displays 45 
remarkable amino acid plasticity in vitro tolerating multiple aa substitutions, many of which have 46 
not yet been observed in nature. Mutant viruses carrying substitutions at residue 145 showed no 47 
major impairment on virus replication in the presence of lower receptor binding avidity. 48 
However, their antigenic characterization confirmed the impact of the 145K substitution in 49 
antibody immunodominance. We provide a better understanding of the functional effects of aa 50 
substitutions implicated in antigenic drift and its consequences on receptor binding and 51 
antigenicity. The mutation analyses presented in this report represent a significant dataset to aid 52 
and test computational approaches’ ability to predict binding of glycans and in antigenic 53 
cartography analyses. 54 
Introduction 55 
The surface hemagglutinin (HA) glycoprotein of influenza A virus (IAV) has a pivotal 56 
role in initiating the virus life cycle by binding to the virus receptor on target cells. HA binds to 57 
sialic acid (SA) residues that occur as terminal monosaccharides in glycoproteins and glycolipids 58 
on the cell surface. SA receptors engaged by IAV are linked to galactose (Gal) in an α2-3 (SAα2-59 
3Gal) or α2-6 (SAα2-6Gal) linkage configuration (1). Located in a small depression on the 60 
globular head of HA, the receptor-binding site (RBS) is composed of the 130-loop, the 150-loop, 61 
the 190-helix and the 220-loop. A series of conserved residues, including Tyr98, Ser136, Trp153, 62 
and His183 (H3 numbering), forms the base of the RBS and are important for SA interaction (2, 63 
3). Although some HA residues on the RBS are critical for receptor specificity (4-6), other 64 
residues may influence binding by modulating virus-receptor binding avidity (7, 8). 65 
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IAV remains an important pathogen for humans and swine (9). While influenza vaccines 66 
are commercially available, the relative effectiveness of these vaccines are heavily dependent on 67 
the antigenic match of vaccine strains to circulating virus strains (10, 11). Most of the humoral 68 
immune response elicited by influenza vaccination or natural exposure is directed against HA to 69 
block virus infection (12, 13). Through a mechanism known as antigenic drift, IAV can 70 
circumvent the preexisting  antibody response by generating genetic variants during replication 71 
with amino acid (aa) substitutions in key HA epitopes on the globular head, allowing for the 72 
emergence of escape mutant viruses (14). Antigenic drift is a frequent cause of reduced vaccine 73 
effectiveness, especially for H3N2 IAVs (15). 74 
Defining the molecular basis of antigenic drift has important implications for 75 
understanding IAV evolution and has been facilitated by methodological advances, such as 76 
antigenic cartography (16). A recent study identified seven residues (145, 155, 156, 158, 159, 77 
189 and 193) on the globular head of the HA as the major determinants of antigenic drift during 78 
the evolution of human H3N2 IAVs (17). Interestingly, all seven residues were located adjacent 79 
to the RBS (17), and therefore these residues may also influence receptor binding. The 80 
importance of this small set of HA residues as major drivers of antigenic evolution has been 81 
demonstrated for IAVs circulating in other hosts, including swine H3N2 IAVs (18).  82 
Antigenic changes in human H3N2 IAVs over the course of time were shown to be 83 
frequently caused by a single aa substitution in one of the seven residues, with specific 84 
substitutions involved in antigenic change more than once (17). One of those substitutions, 85 
N145K, was shown in two separate instances to be the major determinant of antigenic drift 86 
during the evolution of human H3N2 IAVs (16, 17). While there is evidence that N145K caused 87 
large antigenic changes (7, 16-18) and also altered receptor binding avidity (7), it remains 88 
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unclear whether there are functional constraints to substitutions at residue 145 or how alternative 89 
aa substitutions at this residue may affect receptor binding and antigenic properties.  90 
In the present study, we carried out site-directed mutagenesis to prepare a panel of H3 91 
HA mutant viruses carrying a single aa substitution at residue 145 and subsequently evaluated 92 
the impact of substitutions at this key HA residue on receptor binding and antibody recognition. 93 
Our data indicates that residue 145 displayed remarkable amino acid plasticity in vitro tolerating 94 
multiple aa substitutions, many of which have not yet been observed in nature. Mutant viruses 95 
carrying substitutions at residue 145 showed no major impairment on virus replication. While all 96 
substitutions retained binding to SAα2-6Gal glycans compared to wild type, mutant viruses with 97 
substitutions not commonly found in nature displayed diminished receptor binding capacity. 98 
Antigenic characterization confirmed the impact of HA residue 145K in antibody 99 
immunodominance. These findings have important implications for understanding virus 100 
evolution and aiding the development of novel vaccine design approaches. 101 
Results 102 
HA residue 145 displayed remarkable aa plasticity in vitro. The HA N145K substitution results 103 
in significant antigenic changes in both human and swine H3N2 IAVs (7, 16-18). Asparagine 104 
(Asn or N) was the most prevalent aa found at residue 145 across all analyzed hosts (Fig. 1A). In 105 
swine-origin IAVs, around 64% of isolates possessed Asn at residue 145, followed by lysine 106 
(Lys or K) at ~33% and serine (Ser or S) at ~2.5%. In human-origin IAVs, about 42% of isolates 107 
carried Asn, followed by Ser at ~39% and Lys at ~18%. In avian-origin IAVs, the frequency was 108 
~49% for Asn, ~45% for Ser and ~4.6% for glycine (Gly or G). In canine-origin IAVs, around 109 
~73% of isolates possessed Asn, followed by aspartic acid (Asp or D) at ~24%. In equine-origin 110 
IAVs, 99% of isolates carried Asn. Isolates possessing arginine (Arg or R), histidine (His or H), 111 
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isoleucine (Ile or I), cysteine (Cys or C), methionine (Met or M), glutamine (Gln or Q), or 112 
threonine (Thr or T) at residue 145 were found at a frequency below 1%. Alanine (Ala or A), 113 
glutamic acid (Glu or E), leucine (Leu or L), phenylalanine (Phe or F), proline (Pro or P), 114 
tryptophan (Trp or W), tyrosine (Tyr or Y) and valine (Val or V) were not observed in any of the 115 
isolates from analyzed hosts.  116 
To evaluate the impact of substitutions at residue 145, a panel of viruses carrying single 117 
substitutions representing each of the 20 amino acids was generated by reverse genetics (19, 20) 118 
(Fig. 1B). Since these viruses were generated in the context of a swine-origin H3N2 IAV (Fig. 119 
1A), 145N, 145K and 145S are referred as naturally occurring substitutions whereas the 120 
remaining substitutions are termed alternative or non-naturally occurring. Substitutions were 121 
introduced into the HA of A/turkey/Ohio/313053/2004 (H3N2) – herein referred to as OH/04 wt 122 
virus that naturally carries 145N (Fig. 1C). Of the 19 OH/04 HA 145 single aa mutant viruses 123 
rescued, next generation sequencing analysis revealed that 12 substitutions (145A, 145C, 145G, 124 
145H, 145K, 145L, 145M, 145P, 145Q, 145R, 145S and 145T) were well tolerated (98-100% of 125 
sequenced reads possessed the expected codon at residue 145) after 3 passages in MDCK cells. 126 
For substitutions 145F, 145I, 145V and 145Y, the percentage of reads bearing the mutated codon 127 
was around 90% while the remaining 10% of reads showed a partial reversion to the wt codon 128 
(I145N, V145N and Y145N) or a partial transition for a codon specifying Ser (F145S). None of 129 
these HA substitutions led to compensatory substitutions on the HA or neuraminidase (NA) 130 
segments. Three substitutions (145D, 145E and 145W) were not well tolerated, leading to partial 131 
reversion to the wt codon (D145N) or partial transition to a codon specifying either Gly (E145G) 132 
or Leu (W145L). Moreover, additional substitutions emerged on the HA for 145E and 145W 133 
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(T128A) or on the NA for 145E (T148I). For these reasons 145D, 145E and 145W viruses were 134 
excluded from further analysis. 135 
Viruses were assayed for their ability to agglutinate red blood cells (RBCs) from different 136 
species (turkey, chicken, and horse) by standard hemagglutination (HA) assay. Turkey and 137 
chicken RBCs are known to carry both SAα2-3Gal and SAα2-6Gal receptors on their cell surface 138 
while horse RBCs mainly display SAα2-3Gal (21-23). Similar to 145N (wt) virus, nearly all 139 
mutant viruses were found to agglutinate turkey RBCs efficiently, with the exception of 145C 140 
virus that displayed low HA titers (Table 2). In contrast, agglutination of chicken RBCs was less 141 
consistent with HA titers of some mutant viruses comparable to that of the 145N (wt) virus while 142 
other mutant viruses exhibited an 8 to 16-fold decrease in HA titers (145F, 145G, 145V and 143 
145Y viruses) or no agglutination (145C virus) (Table 2). Only the 145F virus showed 144 
detectable, albeit low, HA titers using horse RBCs (Table 2). There was no correlation between 145 
the ability to agglutinate RBCs and virus titers. Due the decreased ability to agglutinate RBCs, 146 
the 145C virus was not tested in further assays. 147 
Viruses were then compared in a multiple-step infection cycle in vitro. MDCK cells were 148 
infected at a low multiplicity of infection (MOI of 0.01). All viruses grew to high titers and 149 
displayed similar growth kinetics (Fig. 2A). There was no discernable difference in peak titers 150 
(~6.5 to 7.0 log10 TCID50/ml equivalents) at 72 hpi, with the exception of 145P and 145H viruses 151 
that showed slightly lower peak titers (~5.5 log10 TCID50/ml equivalents, P <0.001). Taken 152 
together, these results indicate that residue 145 shows high levels of plasticity in vitro despite of 153 
the limited detection of aa variation in nature. Furthermore, single aa substitutions did not have a 154 
major impact in growth kinetics in vitro but modulated the ability of mutant viruses to 155 
agglutinate RBCs from particular hosts. 156 
 8 
Viruses with alternative substitutions at residue 145 retain SAα2-6Gal binding, but frequently 157 
displayed decreased receptor binding avidity. To further expand on the receptor binding 158 
characterization of the 145 mutants, we analyzed whether these substitutions were involved in 159 
modulating receptor avidity or receptor specificity by measuring agglutination of turkey RBCs 160 
previously treated with different concentrations of bacterial neuraminidase (Fig. 2B-C). All of 161 
the mutant viruses bound to desialylated RBCs to a varying degree. Naturally occurring 162 
substitutions showed the highest avidity to receptors. Binding of 145N (wt) virus was 163 
indistinguishable from either the 145K (both neuraminidases) or 145S (C. perfringens 164 
neuraminidase) viruses. Nearly all mutant viruses carrying alternative substitutions at residue 165 
145 displayed decreased receptor binding avidity, with the notable exception of 145M virus that 166 
showed no discernable difference in binding compared to 145N (wt) virus. Overall, the results 167 
suggest differences in avidity regardless of the bacterial neuraminidases tested, although 168 
specificity cannot be completely ruled out. 169 
 Next, we performed a glycan-based ELISA using monospecific preparations of Fet-HRP 170 
as surrogates of binding to SAα2-3Gal (3-Fet-HRP) or SAα2-6Gal (6-Fet-HRP) (24) glycans 171 
(Fig. 3A-P). The assay reliably discriminated receptor binding specificity as evidenced by the 172 
viruses used as controls, with human pH1N1 showing a preference to SAα2-6Gal (Fig. 3Q) 173 
while avian H5N1 displayed restricted binding to SAα2-3Gal (Fig. 3R). All of the mutant 174 
viruses retained binding to SAα2-6Gal with no residual binding to SAα2-3Gal. Naturally 175 
occurring substitutions [145N (wt), 145K and 145S viruses] showed the greatest binding to 176 
SAα2-6Gal (Fig. 3A, G and M). Consistent with differences in avidity from previous results, 177 
mutant viruses carrying alternative substitutions at residue 145 displayed weaker binding to 178 
SAα2-6Gal (Fig. 3B-F, H-L and N-P) compared to viruses possessing naturally occurring 179 
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substitutions. Among mutant viruses carrying alternative substitutions, 145M and 145P viruses 180 
demonstrated the highest binding (Fig. 3I and J) while 145F and 145G showed substantial 181 
decrease in binding to SAα2-6Gal (Fig. 3C and D). Overall, these results suggest substitutions in 182 
HA at residue 145 do not affect receptor specificity but modulate receptor avidity. Nearly all the 183 
alternative substitutions led to decreased receptor binding avidity. 184 
Substitutions at residue 145 modulate binding to a broad range of SAα2-6Gal glycans. To 185 
further compare the impact of substitutions at residue 145 on receptor binding specificity, glycan 186 
array analysis was performed for all viruses using a glycan microarray containing linear, O-187 
linked, and N-linked glycans with extended poly-N-acetyl-lactosamine (poly-LacNAc) repeats 188 
found in human, swine and ferret airway tissues (25). The array provides a broad semi-189 
quantitative view of the binding preference for specific viruses. All of the viruses retained 190 
specificity to SAα2-6Gal glycans (Fig. 4A-P), corroborating the results from the glycan-based 191 
ELISA (Fig. 3). Viruses carrying naturally occurring substitutions showed expanded binding to 192 
nearly all SAα2-6Gal glycan types in the array. OH/04 wt (145N) virus had slightly preferred 193 
binding to O-glycans (Fig. 4A) while 145K virus appeared to favor binding to N-glycans (Fig. 194 
4G). 145S virus binding showed a slight reduction in binding to linear and some of the smaller 195 
O-glycans (Fig. 4M) compared to OH/04 wt (145N) virus (Fig. 4A). There were distinct patterns 196 
of binding for viruses carrying alternative substitutions. 145F, 145L, 145M, 145P 145Q, 145T 197 
and 145V viruses demonstrated binding to a broader range of glycans that was comparable to 198 
OH/04 wt (145N) virus (Fig. 4C, H, I-K, N and O). The 145A, 145G, 145H, 145I, 145R and 199 
145Y mutant viruses displayed a more restricted binding to glycans in the array, although they 200 
appear to maintain a preference to O-linked glycans (Fig. 4B, D, E, F, L and P). Taken together 201 
with the glycan-based ELISA results, these data indicated that while certain substitutions in HA 202 
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at residue 145 lead to broad reductions in binding to SAα2-6Gal glycans, many non-natural 203 
variants appear to be well-tolerated, with only minor variance in receptor specificity detected. 204 
Substitutions at residue 145 modulate sera reactivity. For human H3N2 IAVs, it has been 205 
proposed that the emergence of the HA N145K substitution led to a change in antibody 206 
immunodominance (7). To assess whether a similar phenomenon occurs in swine-origin H3 207 
IAVs and how alternative substitutions at residue 145 affect antigenicity, the sera reactivity of 208 
each mutant virus in the panel was tested by ELISA (Fig. 5A-C) and HI assays (Fig. 6A and B). 209 
For these experiments, swine antisera against NY/11 or IA/14 wild type viruses were tested. The 210 
HA1 domain of these viruses differs by only two amino acids: NY/11 virus possesses 145N/289P 211 
while IA/14 carries 145K/289S. Based on its location at the base of the HA1 globular head and 212 
no prior evidence of an antigenic role, we assume that position 289 is antigenically irrelevant. 213 
Additionally, swine antisera against OH/04 wt virus were tested. To prevent confounding effects, 214 
the HA gene segment of the NY/11 and IA/14 viruses were rescued by reverse genetics in the 215 
background of 7 gene segments from the OH/04 wt virus. The 1+7 NY/11 and IA/14 reverse 216 
genetics viruses were used as controls in ELISA and HI assays.  217 
Reactivity of sera generated against the OH/04 wt virus was similar across the entire 218 
panel of OH/04 145 single aa mutant viruses (Fig. 5A), indicating substitutions at residue 145 in 219 
the context of OH/04 HA do not change antigenicity against wt homologous sera. Consistent 220 
with amino acid divergence between OH/04 wt and control viruses, OH/04 wt virus antisera had 221 
reduced reactivity to both NY/11 and IA/14 control viruses. Surprisingly, sera raised against the 222 
NY/11 virus displayed no discernible difference in reactivity among all of the virus evaluated 223 
regardless of the 145 aa substitution, including the NY/11 and IA/14 viruses (Fig. 5B). As 224 
observed for human H3N2 IAVs, the presence of 145K in a swine-origin IAV results in an 225 
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immunodominant epitope targeted by the antibody response (Fig. 5C). Sera generated against the 226 
IA/14 virus showed decreased reactivity to the NY/11 virus (possessing HA residue 145N) 227 
compared to the IA/14 virus (carrying HA residue 145K). Nearly all of the OH/04 145 single aa 228 
mutant viruses, with the exception of 145K virus, exhibited diminished reactivity to the IA/14 229 
virus antisera. The 145K virus was the only mutant virus to consistently show reactivity more 230 
similar to homologous IA/14 sera generated against the IA/14 virus, confirming the impact of 231 
HA residue 145K in modulating antibody immunodominance. 232 
Antigenic characterization by HI assay was mostly consistent with the ELISA data. The 233 
OH/04 wt virus antisera reacted to all OH/04 145 single aa mutant viruses. Relative to the 145N 234 
(wt) virus, changes in HI titers were almost indistinguishable (Fig. 6A and B). The OH/04 wt 235 
virus antisera had a large reduction in cross-HI reactivity against the IA/14 virus and only a 236 
modest reduction against the NY/11 virus. Similar to the ELISA data, most substitutions at 237 
residue 145 minimally affected NY/11 virus antisera reactivity, with the 145K virus causing the 238 
largest reduction in cross-HI titers. Reactivity of the IA/14 virus antisera was drastically reduced 239 
against nearly all of the OH/04 145 single aa mutant viruses. In agreement with previous results, 240 
the 145K virus was the only mutant virus to show minimal reduction in sera cross-reactivity 241 
compared to IA/14 virus. Collectively, these results indicate that residue 145K has a profound 242 
impact in modulating antibody immunodominance and that sera raised against a 145K bearing 243 
virus can recognize the epitope bearing such substitution in the context of a distinct H3 HA.  244 
Discussion 245 
HA engagement with terminal SA residues on host cells is an essential step in the IAV’s 246 
replication cycle. Not surprisingly, receptor-binding specificity is a major host range restriction 247 
factor. In a simplistic view, IAVs of avian origin prefer binding to SAα2-3Gal glycans whereas 248 
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those that circulate in humans favor binding to SAα2-6Gal receptors (5, 26-28). During human 249 
adaptation of avian-origin IAVs, receptor specificity switch is accompanied by specific 250 
substitutions on the HA (E190D/G225D in the H1 subtype and Q226L/G228S in the H2 and H3 251 
subtypes) (5, 26, 29, 30). While these residues are critical to receptor binding specificity, other 252 
residues on the HA have the potential to affect receptor binding functions, including receptor 253 
binding avidity (7, 8, 23, 31). The identification of up to 7 residues (145, 155, 156, 158, 159, 189 254 
and 193) near the RBS as the major determinants of antigenic drift during the evolution of 255 
human and swine H3N2 IAVs (17, 18, 32) has led to the hypothesis that emerging substitutions 256 
in these residues must drive antigenic change and immune escape without disrupting receptor 257 
binding properties, potentially limiting the flexibility of aa residues in these positions (17, 33). In 258 
agreement with this hypothesis, analysis of HA sequences showed the occurrence of only a small 259 
subset of aa substitutions at these residues that are recycled sporadically (17, 18, 32, 34, 35). 260 
Here we examined the amino acid plasticity at residue 145, one of the identified key 261 
determinants of antigenic drift, by mutating this residue to create a panel of H3 HA mutant 262 
viruses carrying a single aa substitution representing every possible amino acid in a swine H3N2 263 
backbone. HA residue 145 showed extraordinary plasticity with 16 out of 19 substitutions 264 
(145A, 145C, 145F, 145G, 145H, 145I, 145K, 145L, 145M, 145P, 145Q, 145R, 145S, 145T, 265 
145V and 145Y) being well tolerated in vitro (90-100% of sequenced reads possessing the 266 
mutated codon at residue 145). Whether these substitutions are tolerated in vivo is beyond the 267 
scope of the present report and remain to be determined. Consistent with the intricate balance 268 
between immune escape and receptor binding, three substitutions (145D, 145E and 145W) were 269 
not tolerated and led to the emergence of partial reversion at residue 145 and additional 270 
substitutions in either HA (T128A) and/or NA (T148I). HA T128A disrupted a potential 271 
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glycosylation site (36, 37) and was shown to emerge along with a substitution at residue 145 in 272 
human H3N2 IAVs during the 2013-2014 season (34). NA T148I has been associated with 273 
reduced NA activity, decreased susceptibility to neuraminidase inhibitors, and NA-mediated 274 
binding and agglutination (38, 39). The previously reported role of these substitutions suggests 275 
they may be compensatory. 276 
With the exception of 145C virus, there was no discernible difference in the ability of 277 
tested mutant viruses to agglutinate turkey RBCs. Turkey and chicken RBCs carry both SAα2-278 
3Gal and SAα2-6Gal glycans on their cell surface (21-23), and some of tested mutant viruses 279 
exhibited impaired ability to agglutinate chicken RBCs. Loss of the ability to agglutinate RBCs 280 
has plagued the antigenic characterization of recent human H3N2 IAVs (40). As previously 281 
reported for chicken RBCs (41), an in-depth analysis of major glycan structures present on RBCs 282 
from other hosts will help shed light to current issues on antigenic characterization of IAVs.  283 
Using independent assays, we demonstrated that all tested mutant viruses retained some 284 
binding to SAα2-6Gal glycans. However, viruses possessing naturally occurring substitutions 285 
[145N (wt), 145K and 145S] showed the strongest receptor binding. With the exception of 145M 286 
virus, all viruses carrying alternative substitutions (145A, 145C, 145F, 145G, 145H, 145I, 145L, 287 
145P, 145Q, 145R, 145T, 145V and 145Y) displayed decreased ability to bind SAα2-6Gal 288 
receptors. In contrast to other reports, no compensatory substitutions were identified on the HA 289 
or NA by next-generation sequencing (42, 43). This indicates that the observed changes in 290 
receptor binding reported here are directly related to substitutions at residue 145. It is important 291 
to emphasize that although viruses carrying alternative substitutions exhibited decreased receptor 292 
binding avidity in vitro, the lower threshold for biologically relevant avidity in vivo is unknown. 293 
Glycan array analysis revealed a broad range of SAα2-6Gal glycan interactions that were 294 
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modulated by substitutions at residue 145. Interestingly, one of the viruses with the lowest 295 
binding to 6-modified fetuin glycans in the panel (145F virus) displayed extensive binding to 296 
SAα2-6Gal glycans, including extended glycans (25). While the expanded glycan array provides 297 
important insights on the binding preference, which receptors are relevant for IAV attachment 298 
and transmission in vivo remain to be elucidated. Furthermore, the density, distribution and 299 
organization of glycans on host tissues are poorly defined. 300 
As observed in human H3N2 IAVs, the emergence of the HA N145K substitution in 301 
swine H3N2 IAVs led to a change in the antibody immunodominance. It is astonishing that 302 
reactivity to sera raised against a virus possessing HA 145N was indistinguishable among all of 303 
the viruses carrying substitutions at residue 145, but reactivity to sera raised against a virus 304 
possessing HA 145K was highly skewed to recognize an epitope bearing HA residue 145K even 305 
in the context of a distantly related H3 HA, demonstrating the dramatic impact N145K mutants 306 
can have in population immunity. Antibody immunodominance may be key for understanding 307 
antigenic drift and refers to the immunological phenomenon in which the immune system 308 
preferentially mounts a response to complex antigens in a dynamic hierarchical order (14). 309 
Immunodominance hierarchy can occur at the level of viruses within multivalent immunogens, 310 
proteins within viruses, antigenic sites within proteins, epitopes within antigenic sites and, as 311 
showed in the present report and by others, single aa substitutions within epitopes (7, 14, 16, 17, 312 
44, 45). The impact of substitutions at residue 145 on immunogenicity and antibody 313 
immunodominance remains to be fully characterized. While there may be a fitness cost 314 
associated with the emergence of such substitutions in nature, the ability to manipulate the aa 315 
plasticity near the RBS may offer an alternative approach to induce broader protection and, 316 
perhaps, potentially elicit receptor mimicry, broad-spectrum neutralizing antibodies (46). 317 
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The complex and continuous antigenic evolution of IAVs remains a major hurdle for 318 
vaccine selection and effective vaccination. We provide a better understanding of the functional 319 
effects of aa substitutions near the RBS implicated in antigenic drift and its consequences on 320 
receptor binding. The mutation analyses presented in this report represent a significant dataset to 321 
aid and test computational approaches’ ability to predict binding of glycans.  322 
Materials and Methods 323 
Cell culture. Madin-Darby canine kidney (MDCK) and human embryonic kidney 293T cells 324 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 325 
fetal bovine serum (FBS). Cells were propagated at 37˚C in a humidified incubator under 5% 326 
CO2 atmosphere.  327 
Molecular cloning and virus rescue. The OH/04 wt strain is a prototypic swine-origin virus 328 
amenable to genetic manipulation by an established reverse genetics (RG) system (18, 47, 48). 329 
Single aa substitutions representing each of the 20 naturally occurring amino acids (Table 1) 330 
were inserted by site-directed mutagenesis at the codon corresponding to HA residue 145 (H3 331 
numbering). To prevent the carryover of OH/04 wt HA plasmid DNA during PCR amplification, 332 
the cloned OH/04 wt HA segment was split into two overlapping plasmids: pDP-SD1 and pDP-333 
SD2. The pDP-SD1 plasmid carries the mouse RNA polymerase I terminator (t1) (20) followed 334 
by nucleotides 1-522 of OH/04 wt HA segment. The pDP-SD2 plasmid contains nucleotides 335 
500-1762 of OH/04 wt HA segment followed by the human RNA polymerase I promoter (polI) 336 
(20). To introduce the desired mutations into OH/04 wt HA, a PCR fragment containing t1 337 
followed by the 5’ portion of the HA was generated with forward primer 5’-ACC GGA GTA 338 
CTG GTC GAC CTC CGA AGT TGG GGG GGA GCA AAA GCA GG-3’ and the respective 339 
reverse primer (Table 1) using pDP-SD1 as template. Similarly, a PCR fragment comprising the 340 
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3’ portion of HA followed by polI was amplified from pDP-SD2 using reverse primer 5’-ATG 341 
CTG ACA ACG TCC CCG GCC CGG CGC TGC T-3’ and the respective forward primer 342 
(Table 1). All PCR products were purified by gel extraction using QIAquick Gel Extraction Kit 343 
(Qiagen, Valencia, CA) and combined to produce RG-ready PCR-based HA segments for 344 
individual OH/04 HA 145 single aa mutants by overlapping PCR as previously described (19). 345 
All PCR reactions were performed with Phusion High Fidelity DNA polymerase (New England 346 
Biolabs, Ipswich, MA) and confirmed to be free of unwanted mutations by sequencing. Viruses 347 
were rescued by PCR-based RG using a co-culture of 293T/MDCK cells as previously described 348 
(19, 20). To generate OH/04 HA 145 single aa mutant viruses, the respective RG PCR-based HA 349 
segment was paired with the seven plasmids representing the remaining OH/04 wt gene 350 
segments. Following transfection, cells were incubated at 35˚C. After 24 h incubation, media 351 
was replaced with Opti-MEM I (Life Technologies, Carlsbad, CA) containing 1 μg/mL TPCK-352 
trypsin (Worthington Biochemicals, Lakewood, NJ) and 1% antibiotics/antimycotic solution 353 
(Sigma-Aldrich, St. Louis, MO). Following virus rescue, virus stocks were amplified in MDCK 354 
cells. Virus stocks were titrated by tissue culture infectious dose 50 (TCID50) and virus titers 355 
were determined by the Reed and Muench method (49). 356 
Whole-genome sequencing. Virus RNA from tissue culture supernatant virus stocks were 357 
purified using the RNeasy mini kit (Qiagen, Valencia, CA) or MagNA Pure LC RNA Isolation 358 
Kit (Roche Life Science, Mannheim, Germany). Isolated virus RNA served as template in a one-359 
step reverse transcriptase PCR (RT-PCR) reaction for multi-segment, whole genome 360 
amplification (50). Amplicon sequence libraries were prepared as previously described (50) or 361 
using Nextera XT DNA Library Prep Kit (Illumina, San Diego, CA) according to the 362 
manufacturer’s protocol. Barcoded libraries were multiplexed and sequenced on the high-363 
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throughput Illumina MiSeq sequencing platform in a paired-end 150 nt run format. De novo 364 
genome assembly was performed as described previously (50) and HA and NA-specific reads 365 
were mapped to OH/04 reference sequences using Geneious 10.1.3 (51). 366 
In vitro growth kinetics. Confluent monolayers of MDCK cells were inoculated at 0.01 367 
multiplicity of infection (MOI) for each virus. After 1 h incubation, virus inoculum was 368 
removed, and cells washed twice with 1X phosphate-buffered saline (PBS). Then, Opti-MEM I 369 
(Life Technologies, Carlsbad, CA) containing TPCK-trypsin (Worthington Biochemicals, 370 
Lakewood, NJ) and antibiotics/antimycotic solution (Sigma-Aldrich, St. Louis, MO) was added 371 
to the cells. At indicated time points, tissue culture supernatant from inoculated cells was 372 
collected for virus titer quantification. Virus RNA from tissue culture supernatant was isolated 373 
using the MagMAX-96 AI/ND Viral RNA Isolation Kit (Thermo Fisher Scientific, Waltham, 374 
MA). Virus titers were determined using a real-time reverse transcriptase PCR (rRT-PCR) assay 375 
based on the influenza A matrix gene (52). The rRT-PCR was performed in a LightCycler 480 376 
Real Time PCR instrument (Roche Diagnostics, Rotkreuz, Switzerland) using the LightCycler 377 
480 RNA Master Hydrolysis Probes kit (Roche Life Science, Mannheim, Germany). A standard 378 
curve was generated using 10-fold serial dilutions from an OH/04 wt virus stock of known titer 379 
to correlate qPCR crossing point (Cp) values with virus titers, as previously described (53). Virus 380 
titers were expressed as log10 TCID50/ml equivalents. 381 
Hemagglutination (HA) assay. Chicken (Poultry Diagnostic and Research Center, Athens, GA), 382 
turkey (Poultry Diagnostic and Research Center, Athens, GA) and horse (Lampire Biologicals, 383 
Pipersville, PA) red blood cells (RBCs) were prepared from whole blood preparations using 384 
standard techniques (54). Virus HA assays were carried out using 0.5% (vol/vol in PBS) chicken 385 
RBCs, 0.5% (vol/vol in PBS) turkey RBCs or 1% (vol/vol in PBS) horse RBCs. Briefly, 50 l of 386 
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RBC preparations was added to 50 l of two-fold serial dilutions of virus stocks allowed to 387 
incubate at room temperature for 45 min. After incubation agglutination was measured, and data 388 
expressed as the inverse of the highest dilution that allowed full agglutination.  389 
Receptor cell binding assay. The receptor cell binding assay was performed as previously 390 
described (8, 18, 55). Briefly, 10% (vol/vol in PBS) turkey RBCs were pretreated for 1 h at 37°C 391 
with two-fold serial dilutions of bacterial neuraminidase from Arthrobacter ureafaciens (New 392 
England BioLabs, Ipswich, MA) or Clostridium perfringens (New England BioLabs, Ipswich, 393 
MA). Following neuraminidase treatment, treated RBCs were then washed twice with cold PBS, 394 
and then resuspended to 1% (vol/vol in PBS). 50 l of 1% RBCs treated with the different 395 
neuraminidase concentrations were added to 50 l of each virus (8 HAU, as determined on 396 
untreated RBCs) and allowed to incubate at room temperature for 45 min. After incubation 397 
agglutination was measured, and data expressed as the maximal concentration of neuraminidase 398 
that allowed full agglutination. 399 
Solid-phase assay of receptor binding specificity. The receptor-binding specificity was 400 
determined in a solid phase direct binding assay using monospecific preparations of peroxidase 401 
(HRP)-conjugated fetuin (fet-HRP). Monospecific preparations of fet-HRP were synthesized 402 
using 2-3-sialyltransferase from Pasteurella multocida (Sigma, St. Louis, MO) for 3-modified 403 
fetuin (3-fet-HRP) or 2-6-sialyltransferase from Photobacterium damsela (Sigma, St. Louis, 404 
MO) for 6-modified fetuin (6-fet-HRP), essentially as described previously (24). 96-well native 405 
fetuin-coated flat-bottom plates (Greiner Bio-One, Monroe, NC) were incubated overnight at 4ºC 406 
with 128 HAU of each virus in 0.02 M tris-buffered saline (TBS), pH 7.2–7.4. Virus samples 407 
were run in duplicate. Plates were washed three times with PBS and blocked with blocking 408 
solution [BS, PBS containing 0.1% neuraminidase-treated bovine serum albumin (BSA-NA)] for 409 
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2 h at room temperature. After blocking, plates were washed twice with ice-cold washing 410 
solution (WS, PBS containing 0.02% Tween 80) and incubated with two-fold serial dilution of 3-411 
Fet-HRP (SAα2-3Gal) or 6-Fet-HRP (SAα2-6Gal) in reaction solution (RS, PBS containing 412 
0.02% Tween-80, 0.1% BSA-NA and 2 µM oseltamivir carboxylate) for 1 h at 4ºC. After 413 
incubation, plates were washed five times with ice-cold WS before adding freshly prepared 414 
substrate solution (SS, 0.01% 3,3',5,5'-tetramethylbenzidine in 0.05 M sodium acetate with 415 
0.03% H202). Reactions were allowed to proceed at room temperature for 30 min unless 416 
otherwise stated. Reactions were stopped with 3% (vol/vol in ddH2O) H2SO4. Absorbance 417 
readings were obtained at 450 nm using a Victor x3 Multilabel Plate Reader (PerkinElmer, 418 
Waltham, MA). 419 
Glycan array analysis. Virus stocks were grown in MDCK cells, clarified by low-speed 420 
centrifugation, and inactivated by treatment with 0.1% -propiolactone (BPL) for 1 day at 4°C. 421 
Inactivated virus stocks were concentrated as described previously (56). Concentrated virus 422 
stocks were resuspended in PBS with 5% glycerol to HAU, aliquoted and stored at −80°C. HA 423 
titers of concentrated virus stocks were determined by HA assay using 0.5% (vol/vol in PBS) 424 
turkey RBCs. Glycan array analysis was performed using an NHS ester-coated glass microarray 425 
slide containing six replicates of 128 diverse synthetic sialic acid-containing glycans, including 426 
terminal sequences as well as N-linked and O-linked glycans found on mammalian and avian 427 
glycoproteins and glycolipids (25). Whole influenza virus samples were diluted to 256 HAU in 428 
PBS containing 3% BSA (PBS-BSA) and incubated on the array surface for 1 h at room 429 
temperature in a humidity-controlled chamber. After incubation, slides were washed in PBS and 430 
incubated with OH/04 wt swine antisera (18) diluted 1:200 in PBS-BSA for 1 h. Slides were 431 
washed in PBS and incubated for 1 h in goat anti-pig IgG conjugated to fluorescein 432 
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isothiocyanate (FITC; Thermo Fisher Scientific, Waltham, MA) diluted in PBS-BSA (20 g/ml 433 
final concentration). Slides were washed twice in PBS, and in dH2O, then dried prior to 434 
detection. Slide scanning to detect bound virus was conducted using an InnoScan 1100AL 435 
(Innopsys, Carbonne, France) fluorescent microarray scanner. Fluorescent signal intensity was 436 
measured using Mapix (Innopsys, Carbonne, France) and mean intensity minus mean 437 
background of 4 replicate spots was calculated. A complete list of the glycans present in the 438 
array is presented in Supplementary Table 1. The array is comprised of non-sialoside control 439 
(1-10; Grey), SAα2-3Gal (11-76; Yellow) and SAα2-6Gal (77-128; Green) glycans. Glycans are 440 
grouped by structure type: L, linear; O, O-linked; N, N-linked and L
x
, sialyl Le
x
. 441 
Antisera. Swine antisera against A/swine/New York/A01104005/2011 (H3N2) [NY/11], 442 
A/swine/Iowa/A01480656/2014 (H3N2) [IA/14] and A/turkey/Ohio/313053/2004 (H3N2) 443 
[OH/04] were generated in previous studies (18, 32). For each virus, two pigs were primed and 444 
boosted intramuscularly with UV-inactivated whole virus vaccine prepared with commercial oil-445 
in-water adjuvant (1:5 ratio; Emulsigen D, MVP Laboratories, Inc., Ralston, NE). The pigs were 446 
humanely euthanized for blood collection.  447 
Hemagglutination inhibition (HI) assay. HI assays were performed as previously described (54). 448 
Prior to HI testing, swine antisera were treated overnight with receptor-destroying enzyme 449 
(Denka Seiken, Tokyo, Japan) and heat inactivated at 56°C for 30 min. Serial two-fold dilutions 450 
starting at 1:10 were tested for the ability to inhibit the agglutination of 0.5% turkey RBCs with 4 451 
HAU of each virus. HI titers were recorded as the inverse of the highest dilution that inhibited 452 
hemagglutination. 453 
Enzyme-linked immunosorbent assay (ELISA). For ELISA, 96-well flat-bottom plates (Greiner 454 
Bio-One, Monroe, NC) were incubated overnight at 4ºC with 16 HAU of each virus in 1X 455 
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coating solution (Seracare, Milford, MA). Virus samples were run in duplicate. Plates were 456 
blocked with StartingBlock (PBS) blocking buffer (Thermo Fisher Scientific, Waltham, MA) for 457 
1 h at room temperature. After blocking, plates were washed three times with PBS containing 458 
0.05% tween 20 (PBS-T). Two-fold serial dilutions of swine antisera were added and allowed to 459 
incubate for 1 h at room temperature. After incubation, plates were washed three times with 460 
PBS-T before adding the secondary goat anti-swine IgG-HRP HRP-conjugated polyclonal 461 
antibody (Seracare, Milford, MA). Plates were incubated at room temperature for 1 h. After 462 
incubation, plates were washed three times with PBS-T before adding freshly prepared SS buffer 463 
or 2, 2'-azino-di(3-ethylbenzthiazoline-6-sulfonate) [ABTS] 1-component microwell peroxidase 464 
substrate (Seracare, Milford, MA) for 1 h at room temperature. The reaction was stopped by 465 
adding 3% (vol/vol in ddH2O) H2SO4 or ABTS peroxidase stop solution (Seracare, Milford, 466 
MA), respectively. Absorbance readings were obtained at 405 nm using a Victor x3 Multilabel 467 
Plate Reader (PerkinElmer, Waltham, MA). 468 
Statistical analysis. All statistical analyses were performed using the GraphPad Prism Software 469 
Version 7 (GraphPad Software Inc., San Diego, CA). For multiple comparisons, one-way or two-470 
way ANOVA followed by a post-hoc Tukey test were performed. When indicated, a P value 471 
below 0.05 (P<0.05) was considered significant. 472 
Structure modeling. A model of the structure of the HA of A/turkey/Ohio/313053/2004 (H3N2) 473 
was built by homology modeling using Modeller v9.16 (57) based upon the crystal structure of 474 
multiple H3 HA proteins [Protein Data Bank (PDB) codes 2YP7, 1HA0, 2YP2, 4WE8 and 475 
4WE5). The generated model was subsequently rendered with PyMOL v2.1 (58). 476 
Computational analysis of HA sequences. The frequency distribution of aa identities at residue 477 
145 (H3 numbering) was computed using the sequence variation analysis tool in the Influenza 478 
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Research Database (IRD) (59). HA aa sequences from IAVs of the H3 subtype isolated from 479 
swine, human, avian, canine and equine hosts and publicly available in the IRD as of September 480 
06, 2017 were analyzed. For humans, the frequency was calculated from precomputed data in the 481 
IRD database. Only amino acids that reached a frequency of at least 1% are labeled in the plot 482 
legend. 483 
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Figure legends 692 
Figure 1. Amino acid plasticity at residue 145. (A) Publicly available H3 HA sequences were 693 
retrieved and the relative frequency of identified amino acids at residue 145 were calculated for 694 
swine, human, avian, canine and equine AIVs. Amino acids present at frequency below 1% are 695 
not labeled in the figure. (B) Schematic representation of the HA gene segment of 696 
A/turkey/Ohio/313053/2004 (H3N2) depicting the codon corresponding to residue 145 and 697 
respective amino acid substitutions introduced by site-directed mutagenesis. (C) HA monomeric 698 
structure of A/turkey/Ohio/313053/2004 (H3N2) indicating the location of HA residue 145. 699 
Figure 2. Substitutions at residue 145 show no major impact on virus growth but decrease 700 
receptor binding avidity. A) Confluent monolayers of MDCK cells were inoculated with H3 701 
viruses carrying amino acid substitutions at residue 145 at a MOI of 0.01 and incubated at 37°C. 702 
At 6, 12, 24, 48, and 72 hpi, tissue culture supernatants from inoculated cells were collected for 703 
virus RNA quantification by rRT-PCR and expressed as log10 TCID50/ml equivalents. Plotted 704 
data represent means  standard errors (SD). Turkey red blood cells pretreated with different 705 
amounts of neuraminidase from either (B) Clostridium perfringens or (C) Arthrobacter 706 
ureafaciens were mixed with H3 viruses carrying amino acid substitutions at residue 145 to 707 
quantify virus agglutination as measure of virus binding avidity. Data are expressed as the 708 
maximal amount of neuraminidase that allowed full agglutination. (B) and (C) are representative 709 
data of one out of 2 and 3 independent experiments, respectively, with samples run in duplicates 710 
in each experiment. Plotted data represent means  standard errors (SD). 711 
Figure 3. Substitutions at residue 145 retain binding to SAα2-6Gal. H3 viruses carrying 712 
amino acid substitutions at residue 145 were tested for receptor binding specificity with varying 713 
concentrations of SAα2-3Gal (α2-3-linked SA) or SAα2-6Gal (α2-6-linked SA). (A) 145N (wt), 714 
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(B) 145A, (C) 145F, (D) 145G, (E) 145H, (F) 145I, (G) 145K, (H) 145L, (I) 145M, (J) 145P, (K) 715 
145Q, (L) 145R, (M) 145S, (N) 145T, (O) 145V and (P) 145Y viruses. (Q) Human pH1N1 and 716 
(R) avian H5N1 were used as binding control to SAα2-6Gal and SAα2-3Gal, respectively. 717 
Glycan concentration is expressed as arbitrary units (AU). Plotted data represent means  718 
standard errors (SD). Data is representative of 2 independent experiments with 2 replicates per 719 
experiment. 720 
Figure 4. Substitutions at residue 145 modulate binding to a broad range of SAα2-6Gal 721 
glycans. Glycan microarray analysis of H3 viruses carrying amino acid substitutions at residue 722 
145. The array is comprised of non-sialoside control (1-10; Grey), SAα2-3Gal (11-76; Yellow) 723 
and SAα2-6Gal (77-128; Green) glycans. Glycans are grouped by structure type: L, linear; O, O-724 
linked; N, N-linked and L
x
, sialyl Le
x
. (A) 145N (wt), (B) 145A, (C) 145F, (D) 145G, (E) 145H, 725 
(F) 145I, (G) 145K, (H) 145L, (I) 145M, (J) 145P, (K) 145Q, (L) 145R, (M) 145S, (N) 145T, (O) 726 
145V and (P) 145Y viruses. Plotted data represent means  standard errors (SD) using four 727 
replicates per virus. RFU, relative fluorescent units.  728 
Figure 5. Substitutions at residue 145 modulate sera reactivity. Antibody responses to H3 729 
viruses carrying amino acid substitutions at residue 145 was determined by ELISA using swine 730 
antisera generated against (A) OH/04, (B) NY/11 possessing HA residue 145N or (C) IA/14 731 
possessing HA residue 145K. Two sets of sera were tested independently. The first set of sera 732 
was tested 2 times in duplicates. The second set of sera was tested only once in duplicate. Plotted 733 
data represent means  standard errors (SD). O.D., optical density.  734 
Figure 6. Substitutions at residue 145 impact HI titers. HI titers were measured against H3 735 
viruses carrying amino acid substitutions at residue 145 using swine antisera generated against 736 
OH/04 (cyan), NY/11 possessing HA residue 145N (red) or IA/14 possessing HA residue 145K 737 
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(light green). (A and B) two sets of sera were tested independently. The first set of sera was 738 
tested 3 times in duplicates. Confirmatory tests were run on a second set of sera, which tested 739 
once in duplicates. Sera reactivity of all H3 mutant viruses to the respective swine antisera are 740 
depicted as fold change [(log2 HI titer mutant virus)/(log2 HI titer homologous virus)]. Plotted 741 
data represent means  standard errors (SD).  Colors are based on the antigenic cluster 742 
designation for swine H3N2 IAVs.  743 
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Tables 744 
Table 1. Primers used to introduce amino acid substitutions at residue 145 
aa at position 145 Forward primer sequence (5’-3’)* Reverse primer sequence (5’-3’)* 
A GGAATCTGTTGCTAGTTTCTTTAGTAGATT TAAAGAAACTAGCAACAGATTCCCTTCT 
C GGAATCTGTTTGTAGTTTCTTTAGTAGATT TAAAGAAACTACAAACAGATTCCCTTCT 
D GGAATCTGTTGATAGTTTCTTTAGTAGATT TAAAGAAACTATCAACAGATTCCCTTCT 
E GGAATCTGTTGAAAGTTTCTTTAGTAGATT TAAAGAAACTTTCAACAGATTCCCTTCT 
F GGAATCTGTTTTTAGTTTCTTTAGTAGATT TAAAGAAACTAAAAACAGATTCCCTTCT 
G GGAATCTGTTGGAAGTTTCTTTAGTAGATT TAAAGAAACTTCCAACAGATTCCCTTCT 
H GGAATCTGTTCATAGTTTCTTTAGTAGATT TAAAGAAACTATGAACAGATTCCCTTCT 
I GGAATCTGTTATAAGTTTCTTTAGTAGATT TAAAGAAACTTATAACAGATTCCCTTCT 
K GGAATCTGTTAAAAGTTTCTTTAGTAGATT TAAAGAAACTTTTAACAGATTCCCTTCT 
L GGAATCTGTTCTCAGTTTCTTTAGTAGATT TAAAGAAACTGAGAACAGATTCCCTTCT 
M GGAATCTGTTATGAGTTTCTTTAGTAGATT TAAAGAAACTCATAACAGATTCCCTTCT 
P GGAATCTGTTCCAAGTTTCTTTAGTAGATT TAAAGAAACTTGGAACAGATTCCCTTCT 
Q GGAATCTGTTCAAAGTTTCTTTAGTAGATT TAAAGAAACTTTGAACAGATTCCCTTCT 
R GGAATCTGTTCGGAGTTTCTTTAGTAGATT TAAAGAAACTCCGAACAGATTCCCTTCT 
S GGAATCTGTTAGCAGTTTCTTTAGTAGATT TAAAGAAACTGCTAACAGATTCCCTTCT 
T GGAATCTGTTACAAGTTTCTTTAGTAGATT TAAAGAAACTTGTAACAGATTCCCTTCT 
V GGAATCTGTTGTCAGTTTCTTTAGTAGATT TAAAGAAACTGACAACAGATTCCCTTCT 
W GGAATCTGTTTGGAGTTTCTTTAGTAGATT TAAAGAAACTCCAAACAGATTCCCTTCT 
Y GGAATCTGTTTATAGTTTCTTTAGTAGATT TAAAGAAACTATAAACAGATTCCCTTCT 
*Bold nucleotides indicate the mutated codon associated to HA residue 145. 
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Table 2. Agglutination of erythrocytes by OH/04 145 single aa mutant viruses  
aa at position 145 HA titer (HAU) 
0.5% turkey RBCs 0.5% chicken RBCs 1% horse RBCs 
N (wt) 128 256 <2 
A 128 64 <2 
C 4 <2 <2 
F 128 16 8 
G 128 32 <2 
H 256 128 <2 
I 128 64 <2 
K 128 128 <2 
L 128 128 <2 
M 128 128 <2 
P 128 64 <2 
Q 256 128 <2 
R 128 64 <2 
S 128 128 <2 
T 128 64 <2 
V 128 32 <2 
Y 128 32 <2 
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